RevolKa announces the closing of ￥250 million series A extension funding to accelerate Drug-Discovery programs
RevolKa announces the closing of ￥250 million series A extension funding to accelerate Drug-Discovery programs
RevolKa Started joint research of a drug discovery program for rare diseases
RevolKa Started joint research of a drug discovery program for rare diseases
RevolKa launched a drug discovery program for rare diseases
RevolKa launched a drug discovery program for rare diseases
RevolKa completed the contract research with SEKISUI CHEMICAL CO., LTD
RevolKa completed the contract research with SEKISUI CHEMICAL CO., LTD
RevolKa Signed Master Service Agreement with Daiichi Sankyo
LATEST ARTICLE
ARCHIVE
- 2024/10 (1)
- 2024/08 (4)
- 2024/07 (4)
- 2024/05 (2)
- 2024/04 (2)
- 2024/03 (1)
- 2024/02 (4)
- 2024/01 (2)
- 2023/12 (2)
- 2023/11 (1)
- 2023/10 (2)
- 2023/09 (2)
CATEGORY
View allTAG